{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:19:29Z","timestamp":1788178769750,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>Diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetic retinopathy. While intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy has been considered standard of care, many patients have suboptimal treatment responses. Faricimab, which targets angiopoietin-2 and VEGF-A, has shown efficacy and tolerability in randomized controlled trials (RCTs). As RCT results are often challenging to replicate in real-world practice, this study assessed the impact of faricimab on DME outcomes in Middle Eastern real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Treatment-na\u00efve patients with DME receiving faricimab between 2023 and 2025 with \u22656 months follow-up were examined at five sites in Egypt, Saudi Arabia, and Qatar. Following loading doses, patients were treated with either pro re nata or treat-and-extend regimens. Outcomes included visual acuity (VA), retinal thickness, number of injections, and adverse events (AEs). Data were analyzed separately by site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Eighty-eight eyes were treated across sites, with mean follow-up ranging from 7.6 to 12.5 months. Mean number of faricimab injections ranged from 3.0 to 4.2. Improvements from baseline in VA (mean logarithm of the Minimal Angle of Resolution reductions between \u22120.16 and \u22120.49) and retinal thickness (mean reductions between \u221250.6 \u03bcm and \u2212194.0 \u03bcm) were observed with faricimab treatment at all sites, regardless of differences in treatment protocol or observation time points. No AEs of intra-ocular inflammation or endophthalmitis were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The findings suggest faricimab conferred visual and anatomical improvements in a heterogeneous group of patients with DME in real-world Middle East settings. Further real-world studies are essential to confirm long-term safety and effectiveness in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjopt.sjopt_99_26","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:00:16Z","timestamp":1788156016000},"page":"234-241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of faricimab in treatment-na\u00efve diabetic macular edema: The Middle East perspective"],"prefix":"10.4103","volume":"40","author":[{"given":"Abdulrahman F.","family":"AlBloushi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Bedda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ain Shams University, Cairo, Egypt"},{"name":"Al Mashreq Eye Center, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Souka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt"},{"name":"iCare Eye Center, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alkathery","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Bedda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Samir","sequence":"additional","affiliation":[{"name":"Al Mashreq Eye Center, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"iCare Eye Center, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem A. Abu","family":"Serhan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/jcm13051327","article-title":"The treatment of diabetic retinal edema with intravitreal steroids: How and when","volume":"13","author":"Salvetat","year":"2024","journal-title":"J Clin Med"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"1077669","DOI":"10.3389\/fendo.2022.1077669","article-title":"Diabetic retinopathy: Looking forward to 2030","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/aos.12532","article-title":"Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: A Saudi National Diabetes Registry-based study","volume":"93","author":"Al-Rubeaan","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000314876","article-title":"Epidemiology of diabetic retinopathy in Egypt: A hospital-based study","volume":"45","author":"Macky","year":"2011","journal-title":"Ophthalmic Res"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"1128811","DOI":"10.3389\/fmed.2023.1128811","article-title":"Mechanisms of macular edema","volume":"10","author":"Haydinger","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"131","DOI":"10.15537\/smj.2021.2.25623","article-title":"Saudi Arabia guidelines for diabetic macular edema: A consensus of the Saudi retina group","volume":"42","author":"AlQahtani","year":"2021","journal-title":"Saudi Med J"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","article-title":"Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice","volume":"191","author":"Holekamp","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.xops.2023.100442","article-title":"Rationale and design of VOYAGER: Long-term outcomes of faricimab and port delivery system with ranibizumab for neovascular age-related macular degeneration and diabetic macular edema in clinical practice","volume":"4","author":"Guymer","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/DMSO.S214098","article-title":"Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia","volume":"12","author":"Spooner","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab versus ranibizumab in neovascular age-related macular degeneration: The AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: A review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"R16-20260831"},{"key":"R17-20260831"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.xops.2025.100744","article-title":"Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: A scoping review","volume":"5","author":"Chaudhary","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2147\/OPTH.S513009","article-title":"Twelve-month outcomes of faricimab for patients with sub-optimally responsive diabetic macular oedema: A retrospective single-centre study","volume":"19","author":"El-Badawi","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/APO.0000000000000634","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with diabetic macular edema: 1-year subgroup analysis of the phase III YOSEMITE and RHINE trials","volume":"12","author":"Ishida","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/OPTH.S482948","article-title":"Real-world-data of treatment-na\u00efve and previously treated patients receiving up to 3 injections of faricimab in neovascular age-related macular degeneration","volume":"18","author":"Kunzmann","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.ajoint.2025.100132","article-title":"Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema","volume":"2","author":"Maccauro","year":"2025","journal-title":"AJO International"},{"key":"R24-20260831","first-page":"2388","article-title":"Effectiveness and safety of faricimab in eyes with DME in the United Kingdom: 1-year results from the FARWIDE-DME study","volume":"66","author":"Peto","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s40123-025-01204-0","article-title":"Faricimab in the treatment of exudative neovascular age-related macular degeneration and diabetic macular edema in Italy: The FARIT real world study","volume":"14","author":"Lupidi","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3928\/23258160-20250304-01","article-title":"Early outcomes after initiation of faricimab in patients with diabetic macular edema","volume":"56","author":"Borkar","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/OPTH.S502033","article-title":"Clinical evaluation of faricimab in real-world diabetic macular edema in India-A multicenter observational study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s40123-025-01233-9","article-title":"Does the efficacy, durability, and safety of faricimab for diabetic macular edema in randomized trials translate into real-world settings?","volume":"14","author":"Peto","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R30-20260831","first-page":"e75002","article-title":"Real-world results in treating diabetic macular edema with faricimab at a london-based tertiary eye hospital","volume":"16","author":"Al-Rufayie","year":"2024","journal-title":"Cureus"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"e002467","DOI":"10.1136\/bmjophth-2025-002467","article-title":"First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: A Swiss retina research network report","volume":"11","author":"Saad","year":"2026","journal-title":"BMJ Open Ophthalmol"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_99_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:02:11Z","timestamp":1788177731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_99_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjopt.sjopt_99_26","relation":{},"ISSN":["1319-4534","2542-6680"],"issn-type":[{"value":"1319-4534","type":"print"},{"value":"2542-6680","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}